<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240118194041&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240118194041&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Fri, 19 Jan 2024 00:40:42 +0000</lastbuilddate>
<pubDate>Thu, 18 Jan 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Platelet Mitochondrial Fusion and Function in Vascular Integrity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38236952/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 19;134(2):162-164. doi: 10.1161/CIRCRESAHA.123.323867. Epub 2024 Jan 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38236952/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38236952</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323867>10.1161/CIRCRESAHA.123.323867</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38236952</guid>
<pubDate>Thu, 18 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Tarun Tyagi</dc:creator>
<dc:creator>Timur O Yarovinsky</dc:creator>
<dc:creator>E Vincent S Faustino</dc:creator>
<dc:creator>John Hwa</dc:creator>
<dc:date>2024-01-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Platelet Mitochondrial Fusion and Function in Vascular Integrity</dc:title>
<dc:identifier>pmid:38236952</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323867</dc:identifier>
</item>
<item>
<title>Unleashing the Power of Genetics: PLN Ablation, Phospholambanopathies and Evolving Challenges</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38236951/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 19;134(2):138-142. doi: 10.1161/CIRCRESAHA.123.323053. Epub 2024 Jan 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38236951/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38236951</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323053>10.1161/CIRCRESAHA.123.323053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38236951</guid>
<pubDate>Thu, 18 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Alicia Mattiazzi</dc:creator>
<dc:creator>Evangelia G Kranias</dc:creator>
<dc:date>2024-01-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Unleashing the Power of Genetics: PLN Ablation, Phospholambanopathies and Evolving Challenges</dc:title>
<dc:identifier>pmid:38236951</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323053</dc:identifier>
</item>
<item>
<title>VLDL Biogenesis and Secretion: It Takes a Village</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38236950/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>The production and secretion of VLDLs (very-low-density lipoproteins) by hepatocytes has a direct impact on liver fat content, as well as the concentrations of cholesterol and triglycerides in the circulation and thus affects both liver and cardiovascular health, respectively. Importantly, insulin resistance, excess caloric intake, and lack of physical activity are associated with overproduction of VLDL, hepatic steatosis, and increased plasma levels of atherogenic lipoproteins. Cholesterol and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 19;134(2):226-244. doi: 10.1161/CIRCRESAHA.123.323284. Epub 2024 Jan 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The production and secretion of VLDLs (very-low-density lipoproteins) by hepatocytes has a direct impact on liver fat content, as well as the concentrations of cholesterol and triglycerides in the circulation and thus affects both liver and cardiovascular health, respectively. Importantly, insulin resistance, excess caloric intake, and lack of physical activity are associated with overproduction of VLDL, hepatic steatosis, and increased plasma levels of atherogenic lipoproteins. Cholesterol and triglycerides in remnant particles generated by VLDL lipolysis are risk factors for atherosclerotic cardiovascular disease and have garnered increasing attention over the last few decades. Presently, however, increased risk of atherosclerosis is not the only concern when considering today's cardiometabolic patients, as they often also experience hepatic steatosis, a prevalent disorder that can progress to steatohepatitis and cirrhosis. This duality of metabolic risk highlights the importance of understanding the molecular regulation of the biogenesis of VLDL, the lipoprotein that transports triglycerides and cholesterol out of the liver. Fortunately, there has been a resurgence of interest in the intracellular assembly, trafficking, degradation, and secretion of VLDL by hepatocytes, which has led to many exciting new molecular insights that are the topic of this review. Increasing our understanding of the biology of this pathway will aid to the identification of novel therapeutic targets to improve both the cardiovascular and the hepatic health of cardiometabolic patients. This review focuses, for the first time, on this duality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38236950/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38236950</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323284>10.1161/CIRCRESAHA.123.323284</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38236950</guid>
<pubDate>Thu, 18 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Willemien van Zwol</dc:creator>
<dc:creator>Bart van de Sluis</dc:creator>
<dc:creator>Henry N Ginsberg</dc:creator>
<dc:creator>Jan Albert Kuivenhoven</dc:creator>
<dc:date>2024-01-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>VLDL Biogenesis and Secretion: It Takes a Village</dc:title>
<dc:identifier>pmid:38236950</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323284</dc:identifier>
</item>
<item>
<title>Macrophage Heterogeneity and Efferocytosis: Beyond the M1/M2 Dichotomy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38236949/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 19;134(2):186-188. doi: 10.1161/CIRCRESAHA.123.324011. Epub 2024 Jan 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38236949/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38236949</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324011>10.1161/CIRCRESAHA.123.324011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38236949</guid>
<pubDate>Thu, 18 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Prabhash Kumar Jha</dc:creator>
<dc:creator>Masanori Aikawa</dc:creator>
<dc:creator>Elena Aikawa</dc:creator>
<dc:date>2024-01-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Macrophage Heterogeneity and Efferocytosis: Beyond the M1/M2 Dichotomy</dc:title>
<dc:identifier>pmid:38236949</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324011</dc:identifier>
</item>
<item>
<title>In This Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38236948/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 19;134(2):135. doi: 10.1161/RES.0000000000000653. Epub 2024 Jan 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38236948/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38236948</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000653>10.1161/RES.0000000000000653</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38236948</guid>
<pubDate>Thu, 18 Jan 2024 06:00:00 -0500</pubDate>
<dc:date>2024-01-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>In This Issue</dc:title>
<dc:identifier>pmid:38236948</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000653</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38236947/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 19;134(2):136-137. doi: 10.1161/RES.0000000000000654. Epub 2024 Jan 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38236947/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38236947</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000654>10.1161/RES.0000000000000654</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38236947</guid>
<pubDate>Thu, 18 Jan 2024 06:00:00 -0500</pubDate>
<dc:date>2024-01-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38236947</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000654</dc:identifier>
</item>
<item>
<title>CRISPR Activation Reverses Haploinsufficiency and Functional Deficits Caused by &lt;em>;TTN&lt;/em>; Truncation Variants</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38235591/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>CONCLUSIONS: TTN CRISPR activation rescued TTNtv-related functional deficits despite increasing truncated TTN levels, which provides evidence to support haploinsufficiency as a relevant genetic mechanism underlying heterozygous TTNtvs. CRISPR activation could be developed as a therapeutic to treat a large proportion of TTNtvs.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 18. doi: 10.1161/CIRCULATIONAHA.123.063972. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: <i>TTN</i> truncation variants (TTNtvs) are the most common genetic lesion identified in individuals with dilated cardiomyopathy, a disease with high morbidity and mortality rates. TTNtvs reduce normal TTN (titin) protein levels, produce truncated proteins, and impair sarcomere content and function. Therapeutics targeting TTNtvs have been elusive because of the immense size of TTN, the rarity of specific TTNtvs, and incomplete knowledge of TTNtv pathogenicity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We adapted CRISPR activation using dCas9-VPR to functionally interrogate TTNtv pathogenicity and develop a therapeutic in human cardiomyocytes and 3-dimensional cardiac microtissues engineered from induced pluripotent stem cell models harboring a dilated cardiomyopathy-associated TTNtv. We performed guide RNA screening with custom TTN reporter assays, agarose gel electrophoresis to quantify TTN protein levels and isoforms, and RNA sequencing to identify molecular consequences of TTN activation. Cardiomyocyte epigenetic assays were also used to nominate DNA regulatory elements to enable cardiomyocyte-specific TTN activation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: CRISPR activation of TTN using single guide RNAs targeting either the <i>TTN</i> promoter or regulatory elements in spatial proximity to the <i>TTN</i> promoter through 3-dimensional chromatin interactions rescued TTN protein deficits disturbed by TTNtvs. Increasing TTN protein levels normalized sarcomere content and contractile function despite increasing truncated TTN protein. In addition to <i>TTN</i> transcripts, CRISPR activation also increased levels of myofibril assembly-related and sarcomere-related transcripts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TTN CRISPR activation rescued TTNtv-related functional deficits despite increasing truncated TTN levels, which provides evidence to support haploinsufficiency as a relevant genetic mechanism underlying heterozygous TTNtvs. CRISPR activation could be developed as a therapeutic to treat a large proportion of TTNtvs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38235591/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38235591</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063972>10.1161/CIRCULATIONAHA.123.063972</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38235591</guid>
<pubDate>Thu, 18 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Shahnaz Ghahremani</dc:creator>
<dc:creator>Aditya Kanwal</dc:creator>
<dc:creator>Anthony Pettinato</dc:creator>
<dc:creator>Feria Ladha</dc:creator>
<dc:creator>Nicholas Legere</dc:creator>
<dc:creator>Ketan Thakar</dc:creator>
<dc:creator>Yanfen Zhu</dc:creator>
<dc:creator>Harianto Tjong</dc:creator>
<dc:creator>Andrea Wilderman</dc:creator>
<dc:creator>W Tom Stump</dc:creator>
<dc:creator>Lina Greenberg</dc:creator>
<dc:creator>Michael J Greenberg</dc:creator>
<dc:creator>Justin Cotney</dc:creator>
<dc:creator>Chia-Lin Wei</dc:creator>
<dc:creator>J Travis Hinson</dc:creator>
<dc:date>2024-01-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>CRISPR Activation Reverses Haploinsufficiency and Functional Deficits Caused by &lt;em>;TTN&lt;/em>; Truncation Variants</dc:title>
<dc:identifier>pmid:38235591</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.063972</dc:identifier>
</item>
<item>
<title>Piezo1-Mediated Neurogenic Inflammatory Cascade Exacerbates Ventricular Remodeling After Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38235590/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>CONCLUSIONS: Our findings point to a critical role for Piezo1 in ventricular remodeling at 4 weeks after MI and reveal a neurogenic inflammatory cascade as a previously unknown facet of the neuronal immune signaling axis underlying mechanotransduction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 18. doi: 10.1161/CIRCULATIONAHA.123.065390. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure is associated with a high rate of mortality and morbidity, and ventricular remodeling invariably precedes heart failure. Ventricular remodeling is fundamentally driven by mechanotransduction that is regulated by both the nervous system and the immune system. However, it remains unknown which key molecular factors govern the neuro/immune/cardio axis that underlies mechanotransduction during ventricular remodeling. Here, we investigated whether the mechanosensitive Piezo cation channel-mediated neurogenic inflammatory cascade underlies ventricular remodeling-related mechanotransduction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: By ligating the left coronary artery of rats to establish an in vivo model of chronic myocardial infarction (MI), lentivirus-mediated thoracic dorsal root ganglion (TDRG)-specific Piezo1 knockdown rats and adeno-associated virus-PHP.S-mediated TDRG neuron-specific Piezo1 knockout mice were used to investigate whether Piezo1 in the TDRG plays a functional role during ventricular remodeling Subsequently, neutralizing antibody-mediated TDRG IL-6 (interleukin-6) inhibition rats and adeno-associated virus-PHP.S-mediated TDRG neuron-specific IL-6 knockdown mice were used to determine the mechanism underlying neurogenic inflammation. Primary TDRG neurons were used to evaluate Piezo1 function in vitro.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Expression of Piezo1 and IL-6 was increased, and these factors were functionally activated in TDRG neurons at 4 weeks after MI. Both knockdown of TDRG-specific Piezo1 and deletion of TDRG neuron-specific Piezo1 lessened the severity of ventricular remodeling at 4 weeks after MI and decreased the level of IL-6 in the TDRG or heart. Furthermore, inhibition of TDRG IL-6 or knockdown of TDRG neuron-specific IL-6 also ameliorated ventricular remodeling and suppressed the IL-6 cascade in the heart, whereas the Piezo1 level in the TDRG was not affected. In addition, enhanced Piezo1 function, as reflected by abundant calcium influx induced by Yoda1 (a selective agonist of Piezo1), led to increased release of IL-6 from TDRG neurons in mice 4 weeks after MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings point to a critical role for Piezo1 in ventricular remodeling at 4 weeks after MI and reveal a neurogenic inflammatory cascade as a previously unknown facet of the neuronal immune signaling axis underlying mechanotransduction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38235590/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38235590</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065390>10.1161/CIRCULATIONAHA.123.065390</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38235590</guid>
<pubDate>Thu, 18 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Meiyan Sun</dc:creator>
<dc:creator>Sui Mao</dc:creator>
<dc:creator>Chao Wu</dc:creator>
<dc:creator>Xiaoyong Zhao</dc:creator>
<dc:creator>Chengxiao Guo</dc:creator>
<dc:creator>Jun Hu</dc:creator>
<dc:creator>Shijin Xu</dc:creator>
<dc:creator>Fen Zheng</dc:creator>
<dc:creator>Guoqing Zhu</dc:creator>
<dc:creator>Hui Tao</dc:creator>
<dc:creator>Shufang He</dc:creator>
<dc:creator>Ji Hu</dc:creator>
<dc:creator>Ye Zhang</dc:creator>
<dc:date>2024-01-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Piezo1-Mediated Neurogenic Inflammatory Cascade Exacerbates Ventricular Remodeling After Myocardial Infarction</dc:title>
<dc:identifier>pmid:38235590</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065390</dc:identifier>
</item>
<item>
<title>Novel Role for Cardiolipin as a Target of Therapy to Mitigate Myocardial Injury Caused by Venoarterial Extracorporeal Membrane Oxygenation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38235580/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>CONCLUSIONS: We identified a novel mechanism by which VA-ECMO promotes myocardial injury and further identify cardiolipin as an important target of therapy to reduce infarct size and to preserve mitochondrial function in the setting of VA-ECMO for acute myocardial infarction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 18. doi: 10.1161/CIRCULATIONAHA.123.065298. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiolipin is a mitochondrial-specific phospholipid that maintains integrity of the electron transport chain (ETC) and plays a central role in myocardial ischemia/reperfusion injury. Tafazzin is an enzyme that is required for cardiolipin maturation. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) use to provide hemodynamic support for acute myocardial infarction has grown exponentially, is associated with poor outcomes, and is under active clinical investigation, yet the mechanistic effect of VA-ECMO on myocardial damage in acute myocardial infarction remains poorly understood. We hypothesized that VA-ECMO acutely depletes myocardial cardiolipin and exacerbates myocardial injury in acute myocardial infarction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We examined cardiolipin and tafazzin levels in human subjects with heart failure and healthy swine exposed to VA-ECMO and used a swine model of closed-chest myocardial ischemia/reperfusion injury to evaluate the effect of VA-ECMO on cardiolipin expression, myocardial injury, and mitochondrial function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Cardiolipin and tafazzin levels are significantly reduced in the left ventricles of individuals requiring VA-ECMO compared with individuals without VA-ECMO before heart transplantation. Six hours of exposure to VA-ECMO also decreased left ventricular levels of cardiolipin and tafazzin in healthy swine compared with sham controls. To explore whether cardiolipin depletion by VA-ECMO increases infarct size, we performed left anterior descending artery occlusion for a total of 120 minutes followed by 180 minutes of reperfusion in adult swine in the presence and absence of MTP-131, an amphipathic molecule that interacts with cardiolipin to stabilize the inner mitochondrial membrane. Compared with reperfusion alone, VA-ECMO activation beginning after 90 minutes of left anterior descending artery occlusion increased infarct size (36±8% versus 48±7%; <i>P</i>&lt;0.001). VA-ECMO also decreased cardiolipin and tafazzin levels, disrupted mitochondrial integrity, reduced electron transport chain function, and promoted oxidative stress. Compared with reperfusion alone or VA-ECMO before reperfusion, delivery of MTP-131 before VA-ECMO activation reduced infarct size (22±8%; <i>P</i>=0.03 versus reperfusion alone and <i>P</i>&lt;0.001 versus VA-ECMO alone). MTP-131 restored cardiolipin and tafazzin levels, stabilized mitochondrial function, and reduced oxidative stress in the left ventricle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We identified a novel mechanism by which VA-ECMO promotes myocardial injury and further identify cardiolipin as an important target of therapy to reduce infarct size and to preserve mitochondrial function in the setting of VA-ECMO for acute myocardial infarction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38235580/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38235580</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065298>10.1161/CIRCULATIONAHA.123.065298</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38235580</guid>
<pubDate>Thu, 18 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Lija Swain</dc:creator>
<dc:creator>Shreyas Bhave</dc:creator>
<dc:creator>Xiaoying Qiao</dc:creator>
<dc:creator>Lara Reyelt</dc:creator>
<dc:creator>Kay Everett</dc:creator>
<dc:creator>Junya Awata</dc:creator>
<dc:creator>Rahul Raghav</dc:creator>
<dc:creator>Sarah N Powers</dc:creator>
<dc:creator>Genya Sunagawa</dc:creator>
<dc:creator>Peter S Natov</dc:creator>
<dc:creator>Elena Mahmoudi</dc:creator>
<dc:creator>Mary Warner</dc:creator>
<dc:creator>Greg Couper</dc:creator>
<dc:creator>Masa Kawabori</dc:creator>
<dc:creator>Satoshi Miyashita</dc:creator>
<dc:creator>Tejasvi Aryaputra</dc:creator>
<dc:creator>Gordon S Huggins</dc:creator>
<dc:creator>Michael T Chin</dc:creator>
<dc:creator>Navin K Kapur</dc:creator>
<dc:date>2024-01-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Novel Role for Cardiolipin as a Target of Therapy to Mitigate Myocardial Injury Caused by Venoarterial Extracorporeal Membrane Oxygenation</dc:title>
<dc:identifier>pmid:38235580</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065298</dc:identifier>
</item>
<item>
<title>Perceived Interpersonal Racism in Relation to Incident Coronary Heart Disease Among Black Women</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38235551/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>CONCLUSIONS: Perceived experiences of interpersonal racism in employment, in housing, and with the police were associated with higher incidence of CHD among Black women, whereas perceived racism in everyday life was not associated with higher risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 18. doi: 10.1161/CIRCULATIONAHA.123.066471. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Racism is highly prevalent in the United States. Few data exist about whether perceived interpersonal racism is associated with risk of coronary heart disease (CHD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We followed 48 305 participants in the Black Women's Health Study through biennial mailed and Internet-based health questionnaires from 1997, when they provided information on perceived interpersonal racism and were free of cardiovascular disease and cancer, until the end of 2019. We averaged participant responses to 5 validated questions about perceived interpersonal racism in everyday activities, such as "people act as if they think you are dishonest." We summed the positive responses to 3 questions about perceived racism in interactions that involved jobs, housing, and police; scores ranged from 0 (no to all) to 3 (yes to all). CHD cases were defined as nonfatal myocardial infarctions confirmed through medical records, fatal cases identified through the National Death Index, and self-reported revascularization events. We used Cox proportional hazard models adjusting for major confounders to estimate hazard ratios (HRs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During 22 years of follow-up, we identified 1947 incident CHD cases. For women who reported experiences of racism in employment, housing, or involving the police relative to women who reported no such experiences, the age-adjusted HR for CHD was 1.35 (95% CI, 1.13-1.61; <i>P</i><sub>trend</sub>=0.006), and the multivariable HR for CHD was 1.26 (95% CI, 1.05-1.51; <i>P</i><sub>trend</sub>=0.05). For women in the highest quartile of perceived interpersonal racism in daily life relative to women in the lowest quartile, the age-adjusted HR for CHD was 1.25 (95% CI, 1.07-1.46; <i>P</i><sub>trend</sub>=0.006). After multivariable adjustment, the HR was attenuated and no longer statistically significant.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Perceived experiences of interpersonal racism in employment, in housing, and with the police were associated with higher incidence of CHD among Black women, whereas perceived racism in everyday life was not associated with higher risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38235551/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38235551</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066471>10.1161/CIRCULATIONAHA.123.066471</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38235551</guid>
<pubDate>Thu, 18 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Shanshan Sheehy</dc:creator>
<dc:creator>Max Brock</dc:creator>
<dc:creator>Julie R Palmer</dc:creator>
<dc:creator>Michelle A Albert</dc:creator>
<dc:creator>Yvette Cozier</dc:creator>
<dc:creator>Lynn Rosenberg</dc:creator>
<dc:date>2024-01-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Perceived Interpersonal Racism in Relation to Incident Coronary Heart Disease Among Black Women</dc:title>
<dc:identifier>pmid:38235551</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066471</dc:identifier>
</item>
<item>
<title>Merging machine learning and patient preference: a novel tool for risk prediction of percutaneous coronary interventions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38233027/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>CONCLUSIONS: Using common pre-procedural risk factors, the BMC2 machine learning models accurately predict post-PCI outcomes. Utilizing patient feedback, the BMC2 models employ a patient-centred tool to clearly display risks to patients and providers (https://shiny.bmc2.org/pci-prediction/). Enhanced risk prediction prior to PCI could help inform treatment selection and shared decision-making discussions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 17:ehad836. doi: 10.1093/eurheartj/ehad836. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Predicting personalized risk for adverse events following percutaneous coronary intervention (PCI) remains critical in weighing treatment options, employing risk mitigation strategies, and enhancing shared decision-making. This study aimed to employ machine learning models using pre-procedural variables to accurately predict common post-PCI complications.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A group of 66 adults underwent a semiquantitative survey assessing a preferred list of outcomes and model display. The machine learning cohort included 107 793 patients undergoing PCI procedures performed at 48 hospitals in Michigan between 1 April 2018 and 31 December 2021 in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) registry separated into training and validation cohorts. External validation was conducted in the Cardiac Care Outcomes Assessment Program database of 56 583 procedures in 33 hospitals in Washington.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall rate of in-hospital mortality was 1.85% (n = 1999), acute kidney injury 2.51% (n = 2519), new-onset dialysis 0.44% (n = 462), stroke 0.41% (n = 447), major bleeding 0.89% (n = 942), and transfusion 2.41% (n = 2592). The model demonstrated robust discrimination and calibration for mortality {area under the receiver-operating characteristic curve [AUC]: 0.930 [95% confidence interval (CI) 0.920-0.940]}, acute kidney injury [AUC: 0.893 (95% CI 0.883-0.903)], dialysis [AUC: 0.951 (95% CI 0.939-0.964)], stroke [AUC: 0.751 (95%CI 0.714-0.787)], transfusion [AUC: 0.917 (95% CI 0.907-0.925)], and major bleeding [AUC: 0.887 (95% CI 0.870-0.905)]. Similar discrimination was noted in the external validation population. Survey subjects preferred a comprehensive list of individually reported post-procedure outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Using common pre-procedural risk factors, the BMC2 machine learning models accurately predict post-PCI outcomes. Utilizing patient feedback, the BMC2 models employ a patient-centred tool to clearly display risks to patients and providers (https://shiny.bmc2.org/pci-prediction/). Enhanced risk prediction prior to PCI could help inform treatment selection and shared decision-making discussions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38233027/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38233027</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad836>10.1093/eurheartj/ehad836</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38233027</guid>
<pubDate>Wed, 17 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>David E Hamilton</dc:creator>
<dc:creator>Jeremy Albright</dc:creator>
<dc:creator>Milan Seth</dc:creator>
<dc:creator>Ian Painter</dc:creator>
<dc:creator>Charles Maynard</dc:creator>
<dc:creator>Ravi S Hira</dc:creator>
<dc:creator>Devraj Sukul</dc:creator>
<dc:creator>Hitinder S Gurm</dc:creator>
<dc:date>2024-01-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Merging machine learning and patient preference: a novel tool for risk prediction of percutaneous coronary interventions</dc:title>
<dc:identifier>pmid:38233027</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad836</dc:identifier>
</item>
<item>
<title>Aerobic, resistance, or combined exercise training and cardiovascular risk profile in overweight or obese adults: the CardioRACE trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38233024/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>CONCLUSIONS: In adults with overweight or obesity, aerobic exercise alone or combined resistance plus aerobic exercise, but not resistance exercise alone, improved composite CVD risk profile compared with the control.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 17:ehad827. doi: 10.1093/eurheartj/ehad827. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: To determine the comparative efficacy of resistance, aerobic, and combined resistance plus aerobic exercise on cardiovascular disease (CVD) risk profile.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This randomized controlled trial enrolled 406 adults aged 35-70 years with overweight or obesity and elevated blood pressure. Participants were randomly assigned to resistance (n = 102), aerobic (n = 101), combined resistance plus aerobic exercise (n = 101), or no-exercise control (n = 102). All exercise participants were prescribed 1 h of time-matched supervised exercise (the combination group with 30 min of each resistance and aerobic exercise) three times per week for 1 year. The primary outcome was the change from baseline to 1 year in the standardized composite Z-score of four well-established CVD risk factors: systolic blood pressure, low-density lipoprotein (LDL) cholesterol, fasting glucose, and per cent body fat.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 406 participants (53% women), 381 (94%) completed 1-year follow-up. Compared with the control group, the composite Z-score decreased at 1 year, which indicates improved CVD risk profile, in the aerobic {mean difference, -0.15 [95% confidence interval (CI): -0.27 to -0.04]; P = .01} and combination [mean difference, -0.16 (95% CI: -0.27 to -0.04); P = .009] groups, but not in the resistance [mean difference, -0.02 (95% CI: -0.14 to 0.09); P = .69] group. Both aerobic and combination groups had greater reductions in the composite Z-score compared with the resistance group (both P = .03), and there was no difference between the aerobic and combination groups (P = .96). Regarding the four individual CVD risk factors, only per cent body fat decreased in all three exercise groups at 1 year, but systolic blood pressure, LDL cholesterol, and fasting glucose did not decrease in any exercise groups, compared with the control group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In adults with overweight or obesity, aerobic exercise alone or combined resistance plus aerobic exercise, but not resistance exercise alone, improved composite CVD risk profile compared with the control.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38233024/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38233024</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad827>10.1093/eurheartj/ehad827</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38233024</guid>
<pubDate>Wed, 17 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Duck-Chul Lee</dc:creator>
<dc:creator>Angelique G Brellenthin</dc:creator>
<dc:creator>Lorraine M Lanningham-Foster</dc:creator>
<dc:creator>Marian L Kohut</dc:creator>
<dc:creator>Yehua Li</dc:creator>
<dc:date>2024-01-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Aerobic, resistance, or combined exercise training and cardiovascular risk profile in overweight or obese adults: the CardioRACE trial</dc:title>
<dc:identifier>pmid:38233024</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad827</dc:identifier>
</item>
<item>
<title>Per-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing Lipoproteins</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38233021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 23;83(3):470-472. doi: 10.1016/j.jacc.2023.09.836.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38233021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38233021</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.836>10.1016/j.jacc.2023.09.836</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38233021</guid>
<pubDate>Wed, 17 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Nicholas A Marston</dc:creator>
<dc:creator>Giorgio E M Melloni</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:creator>Jakub Morze</dc:creator>
<dc:creator>Frederick K Kamanu</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>Christian T Ruff</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:date>2024-01-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Per-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing Lipoproteins</dc:title>
<dc:identifier>pmid:38233021</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.836</dc:identifier>
</item>
<item>
<title>The Cardiovascular Workforce Crisis: Navigating the Present, Planning for the Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38233020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 23;83(3):466-469. doi: 10.1016/j.jacc.2023.12.001.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38233020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38233020</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.001>10.1016/j.jacc.2023.12.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38233020</guid>
<pubDate>Wed, 17 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Thomas M Maddox</dc:creator>
<dc:creator>Edward T A Fry</dc:creator>
<dc:creator>B Hadley Wilson</dc:creator>
<dc:date>2024-01-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Cardiovascular Workforce Crisis: Navigating the Present, Planning for the Future</dc:title>
<dc:identifier>pmid:38233020</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.001</dc:identifier>
</item>
<item>
<title>When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38233019/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism treatment. However, randomized controlled trials suggest that DOACs may not be as efficacious or as safe as the current standard of care in conditions such as mechanical heart valves, thrombotic antiphospholipid syndrome, and atrial fibrillation associated with rheumatic heart disease. DOACs do not provide a net benefit in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 23;83(3):444-465. doi: 10.1016/j.jacc.2023.10.038.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism treatment. However, randomized controlled trials suggest that DOACs may not be as efficacious or as safe as the current standard of care in conditions such as mechanical heart valves, thrombotic antiphospholipid syndrome, and atrial fibrillation associated with rheumatic heart disease. DOACs do not provide a net benefit in conditions such as embolic stroke of undetermined source. Their efficacy is uncertain for conditions such as left ventricular thrombus, catheter-associated deep vein thrombosis, cerebral venous sinus thrombosis, and for patients with atrial fibrillation or venous thrombosis who have end-stage renal disease. This paper provides an evidence-based review of randomized controlled trials on DOACs, detailing when they have demonstrated efficacy and safety, when DOACs should not be the standard of care, where their safety and efficacy are uncertain, and areas requiring further research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38233019/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38233019</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.038>10.1016/j.jacc.2023.10.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38233019</guid>
<pubDate>Wed, 17 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Antoine Bejjani</dc:creator>
<dc:creator>Candrika D Khairani</dc:creator>
<dc:creator>Ali Assi</dc:creator>
<dc:creator>Gregory Piazza</dc:creator>
<dc:creator>Parham Sadeghipour</dc:creator>
<dc:creator>Azita H Talasaz</dc:creator>
<dc:creator>John Fanikos</dc:creator>
<dc:creator>Jean M Connors</dc:creator>
<dc:creator>Deborah M Siegal</dc:creator>
<dc:creator>Geoffrey D Barnes</dc:creator>
<dc:creator>Karlyn A Martin</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Dawn Kleindorfer</dc:creator>
<dc:creator>Manuel Monreal</dc:creator>
<dc:creator>David Jimenez</dc:creator>
<dc:creator>Saskia Middeldorp</dc:creator>
<dc:creator>Mitchell S V Elkind</dc:creator>
<dc:creator>Christian T Ruff</dc:creator>
<dc:creator>Samuel Z Goldhaber</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Mary Cushman</dc:creator>
<dc:creator>John W Eikelboom</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Jeffrey I Weitz</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:date>2024-01-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38233019</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.038</dc:identifier>
</item>
<item>
<title>Addressing Psychologic Distress in Adults With Congenital Heart Disease: Replacing Anxiety With Hope</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38233018/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 23;83(3):442-443. doi: 10.1016/j.jacc.2023.10.040.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38233018/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38233018</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.040>10.1016/j.jacc.2023.10.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38233018</guid>
<pubDate>Wed, 17 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Anne M Valente</dc:creator>
<dc:creator>Fernando Baraona Reyes</dc:creator>
<dc:date>2024-01-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Addressing Psychologic Distress in Adults With Congenital Heart Disease: Replacing Anxiety With Hope</dc:title>
<dc:identifier>pmid:38233018</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.040</dc:identifier>
</item>
<item>
<title>Anxiety and Depression in Adults With Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38233017/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>CONCLUSIONS: In this global sample of adults with congenital heart disease, almost one-third reported elevated symptoms of depression and/or anxiety, which in turn were associated with lower QOL and HS. We strongly advocate for the implementation of strategies to recognize and manage psychological distress in clinical settings. (Patient-Reported Outcomes in Adults With Congenital Heart Disease [APPROACH-IS]; NCT02150603).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 23;83(3):430-441. doi: 10.1016/j.jacc.2023.10.043.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: A comprehensive understanding of adult congenital heart disease outcomes must include psychological functioning. Our multisite study offered the opportunity to explore depression and anxiety symptoms within a global sample.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: In this substudy of the APPROACH-IS (Assessment of Patterns of Patient-Reported Outcomes in Adults With Congenital Heart Disease-International Study), the authors we investigated the prevalence of elevated depression and anxiety symptoms, explored associated sociodemographic and medical factors, and examined how quality of life (QOL) and health status (HS) differ according to the degree of psychological symptoms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants completed the Hospital Anxiety and Depression Scale, which includes subscales for symptoms of anxiety (HADS-A) and depression (HADS-D). Subscale scores of 8 or higher indicate clinically elevated symptoms and can be further categorized as mild, moderate, or severe. Participants also completed analogue scales on a scale of 0 to 100 for QOL and HS. Analysis of variance was performed to investigate whether QOL and HS differed by symptom category.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 3,815 participants from 15 countries (age 34.8 ± 12.9 years; 52.7% female), 1,148 (30.1%) had elevated symptoms in one or both subscales: elevated HADS-A only (18.3%), elevated HADS-D only (2.9%), or elevations on both subscales (8.9%). Percentages varied among countries. Both QOL and HS decreased in accordance with increasing HADS-A and HADS-D symptom categories (P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this global sample of adults with congenital heart disease, almost one-third reported elevated symptoms of depression and/or anxiety, which in turn were associated with lower QOL and HS. We strongly advocate for the implementation of strategies to recognize and manage psychological distress in clinical settings. (Patient-Reported Outcomes in Adults With Congenital Heart Disease [APPROACH-IS]; NCT02150603).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38233017/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38233017</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.043>10.1016/j.jacc.2023.10.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38233017</guid>
<pubDate>Wed, 17 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Adrienne H Kovacs</dc:creator>
<dc:creator>Koen Luyckx</dc:creator>
<dc:creator>Corina Thomet</dc:creator>
<dc:creator>Werner Budts</dc:creator>
<dc:creator>Junko Enomoto</dc:creator>
<dc:creator>Maayke A Sluman</dc:creator>
<dc:creator>Chun-Wei Lu</dc:creator>
<dc:creator>Jamie L Jackson</dc:creator>
<dc:creator>Paul Khairy</dc:creator>
<dc:creator>Stephen C Cook</dc:creator>
<dc:creator>Shanthi Chidambarathanu</dc:creator>
<dc:creator>Luis Alday</dc:creator>
<dc:creator>Mette-Elise Estensen</dc:creator>
<dc:creator>Mikael Dellborg</dc:creator>
<dc:creator>Malin Berghammer</dc:creator>
<dc:creator>Bengt Johansson</dc:creator>
<dc:creator>Andrew S Mackie</dc:creator>
<dc:creator>Samuel Menahem</dc:creator>
<dc:creator>Maryanne Caruana</dc:creator>
<dc:creator>Gruschen Veldtman</dc:creator>
<dc:creator>Alexandra Soufi</dc:creator>
<dc:creator>Susan M Jameson</dc:creator>
<dc:creator>Edward Callus</dc:creator>
<dc:creator>Shelby Kutty</dc:creator>
<dc:creator>Erwin Oechslin</dc:creator>
<dc:creator>Liesbet Van Bulck</dc:creator>
<dc:creator>Philip Moons</dc:creator>
<dc:creator>APPROACH-IS Consortium, International Society for Adult Congenital Heart Disease</dc:creator>
<dc:date>2024-01-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Anxiety and Depression in Adults With Congenital Heart Disease</dc:title>
<dc:identifier>pmid:38233017</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.043</dc:identifier>
</item>
<item>
<title>Erectile Dysfunction and Coronary Artery Disease: Unfortunate Bedfellows</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38233016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 23;83(3):427-429. doi: 10.1016/j.jacc.2023.10.042.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38233016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38233016</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.042>10.1016/j.jacc.2023.10.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38233016</guid>
<pubDate>Wed, 17 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Glenn N Levine</dc:creator>
<dc:date>2024-01-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Erectile Dysfunction and Coronary Artery Disease: Unfortunate Bedfellows</dc:title>
<dc:identifier>pmid:38233016</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.042</dc:identifier>
</item>
<item>
<title>Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38233015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>CONCLUSIONS: The use of a PDE5i in combination with nitrate medication in men with stable coronary artery disease may pose an increased hazard for cardiovascular morbidity and mortality. Careful patient-centered consideration before prescribing PDE5is to patients with cardiovascular disease using nitrate medication is warranted.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 23;83(3):417-426. doi: 10.1016/j.jacc.2023.10.041.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Phosphodiesterase-5 inhibitor (PDE5i) treatment for erectile dysfunction is associated with lower mortality compared with no treatment for erectile dysfunction after myocardial infarction (MI). There are conflicting results regarding the impact of PDE5i treatment on mortality in conjunction with nitrate medication.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to investigate the association between PDE5i treatment and cardiovascular outcomes in men with stable coronary artery disease treated with nitrate medication.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the Swedish Patient Register and the Prescribed Drug Register we included men with previous MI or revascularization in 2006-2013 who had 2 dispensed nitrate prescriptions within 6 months. Exposure was defined as at least 2 filled prescriptions of any PDE5i. We performed multivariable Cox proportional hazard regression to estimate HRs with 95% CIs for all-cause, cardiovascular, and noncardiovascular mortality, MI, heart failure, cardiac revascularization, and major cardiovascular events (MACE).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, 55,777 men were treated with nitrates and 5,710 men with nitrates and a PDE5i. The combined use of PDE5i treatment with nitrates was associated with higher mortality (HR: 1.39; 95% CI: 1.28-1.51), cardiovascular mortality (HR: 1.34; 95% CI: 1.11-1.62), noncardiovascular mortality (HR: 1.40; 95% CI: 1.27-1.54), MI (HR: 1.72; 95% CI: 1.55-1.90), heart failure (HR: 1.67; 95% CI: 1.48-1.90), cardiac revascularization (HR: 1.95; 95% CI: 1.78-2.13), and MACE (HR: 1.70; 95% CI: 1.58-1.83).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The use of a PDE5i in combination with nitrate medication in men with stable coronary artery disease may pose an increased hazard for cardiovascular morbidity and mortality. Careful patient-centered consideration before prescribing PDE5is to patients with cardiovascular disease using nitrate medication is warranted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38233015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38233015</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.041>10.1016/j.jacc.2023.10.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38233015</guid>
<pubDate>Wed, 17 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Ylva Trolle Lagerros</dc:creator>
<dc:creator>Alessandra Grotta</dc:creator>
<dc:creator>Sara Freyland</dc:creator>
<dc:creator>David Grannas</dc:creator>
<dc:creator>Daniel Peter Andersson</dc:creator>
<dc:date>2024-01-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors</dc:title>
<dc:identifier>pmid:38233015</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.041</dc:identifier>
</item>
<item>
<title>Optical Coherence Tomography or Intravascular Ultrasound for Complex PCI: Different Approaches, Similar Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38233014/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 23;83(3):414-416. doi: 10.1016/j.jacc.2023.10.044.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38233014/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38233014</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.044>10.1016/j.jacc.2023.10.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38233014</guid>
<pubDate>Wed, 17 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Davide Capodanno</dc:creator>
<dc:creator>Marco Spagnolo</dc:creator>
<dc:date>2024-01-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Optical Coherence Tomography or Intravascular Ultrasound for Complex PCI: Different Approaches, Similar Outcomes</dc:title>
<dc:identifier>pmid:38233014</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.044</dc:identifier>
</item>
<item>
<title>Particle Number and Characteristics of Lipoprotein(a), LDL, and apoB: Perspectives on Contributions to ASCVD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38233013/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240118194041&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 23;83(3):396-400. doi: 10.1016/j.jacc.2023.11.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38233013/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240118194041&v=2.18.0">38233013</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.008>10.1016/j.jacc.2023.11.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38233013</guid>
<pubDate>Wed, 17 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Sotirios Tsimikas</dc:creator>
<dc:creator>Vera Bittner</dc:creator>
<dc:date>2024-01-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Particle Number and Characteristics of Lipoprotein(a), LDL, and apoB: Perspectives on Contributions to ASCVD</dc:title>
<dc:identifier>pmid:38233013</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.008</dc:identifier>
</item>





























</channel>
</rss>